Madhu Kumar
Stock Analyst at Goldman Sachs
(2.89)
# 1,759
Out of 5,008 analysts
151
Total ratings
56.86%
Success rate
20.31%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $137.58 | +34.47% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $9.50 | -36.84% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $24.90 | +4.42% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $12.21 | +39.23% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $3.18 | +25.79% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $180.57 | -14.16% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $60.64 | -12.60% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $6.35 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $37.50 | +94.67% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $24.36 | +478.82% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $16.40 | +107.32% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.21 | +171.49% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $21.01 | -33.37% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $10.14 | +107.10% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $15.35 | -67.43% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $3.80 | +110.53% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $9.62 | +825.16% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $7.93 | +1,413.24% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $1.02 | +880.39% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $20.54 | +313.83% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.53 | +1,004.82% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $52.91 | +7.73% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.34 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.49 | +60,506.06% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $5.59 | +257.78% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.03 | +9,656.10% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $39.80 | -12.06% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.76 | +7,756.49% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $13.62 | +193.69% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $24.48 | +1,958.82% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $452.00 | -49.12% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $11.60 | +9,598.28% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.51 | +2,549.01% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $36.76 | -41.51% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $70.19 | -66.52% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $137.58
Upside: +34.47%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $9.50
Upside: -36.84%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $24.90
Upside: +4.42%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $12.21
Upside: +39.23%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $3.18
Upside: +25.79%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $180.57
Upside: -14.16%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $60.64
Upside: -12.60%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $6.35
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $37.50
Upside: +94.67%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $24.36
Upside: +478.82%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $16.40
Upside: +107.32%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.21
Upside: +171.49%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $21.01
Upside: -33.37%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $10.14
Upside: +107.10%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $15.35
Upside: -67.43%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $3.80
Upside: +110.53%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $9.62
Upside: +825.16%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $7.93
Upside: +1,413.24%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $1.02
Upside: +880.39%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $20.54
Upside: +313.83%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.53
Upside: +1,004.82%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $52.91
Upside: +7.73%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.34
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.49
Upside: +60,506.06%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $5.59
Upside: +257.78%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.03
Upside: +9,656.10%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $39.80
Upside: -12.06%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.76
Upside: +7,756.49%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $13.62
Upside: +193.69%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $24.48
Upside: +1,958.82%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $452.00
Upside: -49.12%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $11.60
Upside: +9,598.28%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.51
Upside: +2,549.01%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $36.76
Upside: -41.51%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $70.19
Upside: -66.52%